GleamWall
中文EN

DTIL PRECISION BIOSCIENCES INC

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1357874 · Fiscal year ends 05/21

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY6,353.0%
TTM net income YoY53.9%
TTM EPS YoY103.6%
Revenue 3-yr CAGR-4.9%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-80.3%
Net margin-85.6%
FCF margin-115.0%
EBITDA margin-77.8%

Returns

ROE-112.7%
ROA-36.0%
ROIC (approx.)—
Asset turnover0.42x

Leverage & solvency

Liabilities / assets57.0%
Debt / equity0.00x
Current ratio10.47x
Interest coverage-28.56x

Cash quality & payout

Operating cash flow / net income1.34x
Accruals ratio12.4%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$34.26M$68.70M
R&D expense$54.17M$59.56M
SG&A expense$32.24M$35.30M
Operating income-$52.15M-$26.16M
Interest expense$1.42M$1.78M
Pretax income-$45.72M$7.17M
Income tax$0$0
Net income-$45.72M$7.17M
EBITDA-$50.68M-$22.76M
EPS (basic)-3.561.05
EPS (diluted)-3.561.04
Weighted avg. shares (diluted)12.83M6.88M
Balance sheet
Cash & equivalents$110.82M$108.47M
Short-term investments$4.76M$413,000
Receivables$0$229,000
Current assets$118.74M$94.99M
PP&E, net$1.43M$3.09M
Intangibles$1.17M$622,000
Total assets$154.42M$136.39M
Current liabilities$8.91M$14.98M
Total liabilities$62.17M$80.00M
Shareholders' equity$92.25M$56.39M
Shares outstanding24.09M8.20M
Cash flow statement
Operating cash flow-$65.84M-$58.45M
Capital expenditure$85,000$250,000
Free cash flow-$65.93M-$58.70M
Investing cash flow-$634,000-$215,000
Financing cash flow$95.16M$50.45M
Depreciation & amortization$1.47M$3.40M
Stock-based compensation$10.19M$12.60M

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.